Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000875320-26-000098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-19 | 2026-02-17+ | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $483.52 | -977 | 49.0K | -2% | -$472.4K |
| 2026-02-19 | 2026-02-17 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $483.75 | -2,294 | 49.6K | -4% | -$1.11M | |
| 2026-02-19 | 2026-02-17 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +5,789 | 51.9K | +13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-18 | S | D | 368 | $473.68 | 48,650 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | S | D | 609 | $489.46 | 49,018 | D | — | — | |
| 3 | Common | Common Stock | 2026-02-17 | F | D | 2,294 | $483.75 | 49,627 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-17 | A | A | 5,789 | $0.00 | 51,921 | D | — | — | (F1) Restricted stock unit award that vests in installments beginning on February 20, 2027. |